APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Cancer Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Kidney Cancer Therapy Market Analysis and Forecast 2026-2032

29 December 2025191 pages

Choose your research edition.

Industry ResearchKidney Cancer Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Cancer Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Kidney Cancer Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Cancer Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Cancer Therapy Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Kidney Cancer Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Kidney Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Kidney Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Kidney Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Kidney Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Kidney Cancer Therapy include Eisai, Novartis, Merck, Roche, Pfizer, Bayer, Amgen, Sun Pharmaceutical and Hikma Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Kidney Cancer Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Kidney Cancer Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Kidney Cancer Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Kidney Cancer Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Kidney Cancer Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Kidney Cancer Therapy revenue, projected growth trends, production technology, application and end-user industry.

Kidney Cancer Therapy Segment by Company

Eisai

Novartis

Merck

Roche

Pfizer

Bayer

Amgen

Sun Pharmaceutical

Hikma Pharmaceuticals

Exelixis

Bristol-Myers Squibb

Aveo Pharmaceuticals

Kidney Cancer Therapy Segment by Type

Targeted Therapy

Immunotherapy

Surgery

Other

Kidney Cancer Therapy Segment by Application

Renal Cell Carcinoma (RCC)

Transitional Cell Carcinoma (TCC)

Kidney Cancer Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Kidney Cancer Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Kidney Cancer Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancer Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Kidney Cancer Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Player Table 3. Immunotherapy Major Player Table 4. Surgery Major Player Table 5. Other Major Player Table 6. Global Kidney Cancer Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Renal Cell Carcinoma (RCC) Major Player Table 8. Transitional Cell Carcinoma (TCC) Major Player Table 9. Kidney Cancer Therapy Industry Trends Table 10. Kidney Cancer Therapy Industry Drivers Table 11. Kidney Cancer Therapy Industry Opportunities and Challenges Table 12. Kidney Cancer Therapy Industry Restraints Table 13. Global Kidney Cancer Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Kidney Cancer Therapy Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Kidney Cancer Therapy Market Share by Region (2021-2026) Table 16. Global Kidney Cancer Therapy Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Kidney Cancer Therapy Market Share by Region (2027-2032) Table 18. Global Kidney Cancer Therapy Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Kidney Cancer Therapy Revenue Market Share by Players (2021-2026) Table 20. Global Kidney Cancer Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Kidney Cancer Therapy Key Players Headquarters & Area Served Table 22. Global Kidney Cancer Therapy Players, Product Type & Application Table 23. Global Kidney Cancer Therapy Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Kidney Cancer Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Kidney Cancer Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Kidney Cancer Therapy Revenue Market Share by Type (2021-2026) Table 30. Global Kidney Cancer Therapy Revenue Market Share by Type (2027-2032) Table 31. Global Kidney Cancer Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Kidney Cancer Therapy Revenue Market Share by Application (2021-2026) Table 35. Global Kidney Cancer Therapy Revenue Market Share by Application (2027-2032) Table 36. Eisai Company Information Table 37. Eisai Business Overview Table 38. Eisai Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Eisai Kidney Cancer Therapy Product Portfolio Table 40. Eisai Recent Development Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis Kidney Cancer Therapy Product Portfolio Table 45. Novartis Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck Kidney Cancer Therapy Product Portfolio Table 50. Merck Recent Development Table 51. Roche Company Information Table 52. Roche Business Overview Table 53. Roche Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Roche Kidney Cancer Therapy Product Portfolio Table 55. Roche Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Kidney Cancer Therapy Product Portfolio Table 60. Pfizer Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Bayer Kidney Cancer Therapy Product Portfolio Table 65. Bayer Recent Development Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Amgen Kidney Cancer Therapy Product Portfolio Table 70. Amgen Recent Development Table 71. Sun Pharmaceutical Company Information Table 72. Sun Pharmaceutical Business Overview Table 73. Sun Pharmaceutical Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Sun Pharmaceutical Kidney Cancer Therapy Product Portfolio Table 75. Sun Pharmaceutical Recent Development Table 76. Hikma Pharmaceuticals Company Information Table 77. Hikma Pharmaceuticals Business Overview Table 78. Hikma Pharmaceuticals Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Hikma Pharmaceuticals Kidney Cancer Therapy Product Portfolio Table 80. Hikma Pharmaceuticals Recent Development Table 81. Exelixis Company Information Table 82. Exelixis Business Overview Table 83. Exelixis Kidney Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Exelixis Kidney Cancer Therapy Product Portfolio Table 85. Exelixis Recent Development Table 86. Bristol-Myers Squibb Company Information Table 87. Bristol-Myers Squibb Business Overview Table 88. Bristol-Myers Squibb Kidney Cancer Therapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bristol-Myers Squibb Kidney Cancer Therapy Product Portfolio Table 90. Bristol-Myers Squibb Recent Development Table 91. Aveo Pharmaceuticals Company Information Table 92. Aveo Pharmaceuticals Business Overview Table 93. Aveo Pharmaceuticals Kidney Cancer Therapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Aveo Pharmaceuticals Kidney Cancer Therapy Product Portfolio Table 95. Aveo Pharmaceuticals Recent Development Table 96. North America Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Kidney Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Kidney Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Kidney Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Kidney Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 110. China Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 111. China Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 112. China Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 113. China Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Kidney Cancer Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Kidney Cancer Therapy Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Kidney Cancer Therapy Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Kidney Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Kidney Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Kidney Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Kidney Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Kidney Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Kidney Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Kidney Cancer Therapy Image Figure 2. Global Kidney Cancer Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Cancer Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Immunotherapy Image Figure 6. Surgery Image Figure 7. Other Image Figure 8. Global Kidney Cancer Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Kidney Cancer Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Renal Cell Carcinoma (RCC) Image Figure 11. Transitional Cell Carcinoma (TCC) Image Figure 12. Global Kidney Cancer Therapy Market Size (US$ Million) & (2021-2032) Figure 13. Global Kidney Cancer Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Kidney Cancer Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Kidney Cancer Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Kidney Cancer Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Kidney Cancer Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Kidney Cancer Therapy Revenue Market Share by Type (2021-2032) Figure 20. Global Kidney Cancer Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Kidney Cancer Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Kidney Cancer Therapy Revenue Market Share by Application (2021-2032) Figure 23. North America Kidney Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Kidney Cancer Therapy Revenue Share by Type (2021-2032) Figure 25. North America Kidney Cancer Therapy Revenue Share by Application (2021-2032) Figure 26. North America Kidney Cancer Therapy Revenue Share by Country (2021-2032) Figure 27. United States Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Kidney Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Kidney Cancer Therapy Revenue Share by Type (2021-2032) Figure 32. Europe Kidney Cancer Therapy Revenue Share by Application (2021-2032) Figure 33. Europe Kidney Cancer Therapy Revenue Share by Country (2021-2032) Figure 34. Germany Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Kidney Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Kidney Cancer Therapy Revenue Share by Type (2021-2032) Figure 44. China Kidney Cancer Therapy Revenue Share by Application (2021-2032) Figure 45. Asia Kidney Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Kidney Cancer Therapy Revenue Share by Type (2021-2032) Figure 47. Asia Kidney Cancer Therapy Revenue Share by Application (2021-2032) Figure 48. Asia Kidney Cancer Therapy Revenue Share by Region (2021-2032) Figure 49. Japan Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Kidney Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Kidney Cancer Therapy Revenue Share by Type (2021-2032) Figure 57. SAMEA Kidney Cancer Therapy Revenue Share by Application (2021-2032) Figure 58. SAMEA Kidney Cancer Therapy Revenue Share by Country (2021-2032) Figure 59. Brazil Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Kidney Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Immunotherapy
  • Surgery
  • Other
Applications
  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC)
Companies covered
  • Eisai
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • Bayer
  • Amgen
  • Sun Pharmaceutical
  • Hikma Pharmaceuticals
  • Exelixis
  • Bristol-Myers Squibb
  • Aveo Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Kidney Cancer Therapy Market by Type
  3. 1.2.1 Global Kidney Cancer Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Immunotherapy
  6. 1.2.4 Surgery
  7. 1.2.5 Other
  8. 1.3 Kidney Cancer Therapy Market by Application
  9. 1.3.1 Global Kidney Cancer Therapy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Renal Cell Carcinoma (RCC)
  11. 1.3.3 Transitional Cell Carcinoma (TCC)
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Kidney Cancer Therapy Market Dynamics
  1. 2.1 Kidney Cancer Therapy Industry Trends
  2. 2.2 Kidney Cancer Therapy Industry Drivers
  3. 2.3 Kidney Cancer Therapy Industry Opportunities and Challenges
  4. 2.4 Kidney Cancer Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Kidney Cancer Therapy Market Perspective (2021-2032)
  2. 3.2 Global Kidney Cancer Therapy Growth Trends by Region
  3. 3.2.1 Global Kidney Cancer Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Kidney Cancer Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Kidney Cancer Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Kidney Cancer Therapy Revenue by Players
  2. 4.1.1 Global Kidney Cancer Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Kidney Cancer Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Kidney Cancer Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Kidney Cancer Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Kidney Cancer Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Kidney Cancer Therapy Players, Product Type & Application
  8. 4.5 Global Kidney Cancer Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Kidney Cancer Therapy Market CR5 and HHI
  11. 4.6.3 2025 Kidney Cancer Therapy Tier 1, Tier 2, and Tier 3
5 Kidney Cancer Therapy Market Size by Type
  1. 5.1 Global Kidney Cancer Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Kidney Cancer Therapy Revenue Market Share by Type (2021-2032)
6 Kidney Cancer Therapy Market Size by Application
  1. 6.1 Global Kidney Cancer Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Kidney Cancer Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Kidney Cancer Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eisai
  2. 7.1.1 Eisai Company Information
  3. 7.1.2 Eisai Business Overview
  4. 7.1.3 Eisai Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Kidney Cancer Therapy Product Portfolio
  6. 7.1.5 Eisai Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Kidney Cancer Therapy Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Kidney Cancer Therapy Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Kidney Cancer Therapy Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Kidney Cancer Therapy Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Kidney Cancer Therapy Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Kidney Cancer Therapy Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 Sun Pharmaceutical
  44. 7.8.1 Sun Pharmaceutical Company Information
  45. 7.8.2 Sun Pharmaceutical Business Overview
  46. 7.8.3 Sun Pharmaceutical Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sun Pharmaceutical Kidney Cancer Therapy Product Portfolio
  48. 7.8.5 Sun Pharmaceutical Recent Developments
  49. 7.9 Hikma Pharmaceuticals
  50. 7.9.1 Hikma Pharmaceuticals Company Information
  51. 7.9.2 Hikma Pharmaceuticals Business Overview
  52. 7.9.3 Hikma Pharmaceuticals Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hikma Pharmaceuticals Kidney Cancer Therapy Product Portfolio
  54. 7.9.5 Hikma Pharmaceuticals Recent Developments
  55. 7.10 Exelixis
  56. 7.10.1 Exelixis Company Information
  57. 7.10.2 Exelixis Business Overview
  58. 7.10.3 Exelixis Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Exelixis Kidney Cancer Therapy Product Portfolio
  60. 7.10.5 Exelixis Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Kidney Cancer Therapy Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
  67. 7.12 Aveo Pharmaceuticals
  68. 7.12.1 Aveo Pharmaceuticals Company Information
  69. 7.12.2 Aveo Pharmaceuticals Business Overview
  70. 7.12.3 Aveo Pharmaceuticals Kidney Cancer Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Aveo Pharmaceuticals Kidney Cancer Therapy Product Portfolio
  72. 7.12.5 Aveo Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Kidney Cancer Therapy Revenue (2021-2032)
  2. 8.2 North America Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Kidney Cancer Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Kidney Cancer Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Kidney Cancer Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Kidney Cancer Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Kidney Cancer Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Kidney Cancer Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Kidney Cancer Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Kidney Cancer Therapy Revenue by Country
  11. 8.6.1 North America Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Kidney Cancer Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Kidney Cancer Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Kidney Cancer Therapy Revenue (2021-2032)
  2. 9.2 Europe Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Kidney Cancer Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Kidney Cancer Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Kidney Cancer Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Kidney Cancer Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Kidney Cancer Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Kidney Cancer Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Kidney Cancer Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Kidney Cancer Therapy Revenue by Country
  11. 9.6.1 Europe Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Kidney Cancer Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Kidney Cancer Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Kidney Cancer Therapy Revenue (2021-2032)
  2. 10.2 China Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Kidney Cancer Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Kidney Cancer Therapy Revenue by Type (2027-2032)
  5. 10.3 China Kidney Cancer Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Kidney Cancer Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Kidney Cancer Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Kidney Cancer Therapy Revenue by Application (2027-2032)
  9. 10.5 China Kidney Cancer Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Kidney Cancer Therapy Revenue (2021-2032)
  2. 11.2 Asia Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Kidney Cancer Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Kidney Cancer Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Kidney Cancer Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Kidney Cancer Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Kidney Cancer Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Kidney Cancer Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Kidney Cancer Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Kidney Cancer Therapy Revenue by Country
  11. 11.6.1 Asia Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Kidney Cancer Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Kidney Cancer Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Kidney Cancer Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Kidney Cancer Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Kidney Cancer Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Kidney Cancer Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Kidney Cancer Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Kidney Cancer Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Kidney Cancer Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Kidney Cancer Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Kidney Cancer Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Kidney Cancer Therapy Revenue by Country
  11. 12.6.1 SAMEA Kidney Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Kidney Cancer Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Kidney Cancer Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst